1️⃣ RGX-202 puts Duchenne gene therapy back on FDA’s desk REGENXBIO said RGX-202 met the Phase III primary endpoint, with 93% of evaluable patients above 10% microdystrophin at Week 12, and is now aiming for accelerated approval in 2027.
💡 Why it matters Duchenne gene therapy is still safety-shadowed. A cleaner pivotal file could reopen risk appetite, but FDA still has to bless the surrogate.
☕ Coffee talk How much safety comfort does FDA need before microdystrophin starts carrying the file again?
2️⃣ BMS makes China BD too big to ignore Bristol Myers Squibb and Hengrui signed a 13-program oncology, hematology and immunology collaboration worth up to $15.2B, including a $600M upfront payment.
💡 Why it matters This is not single-asset shopping. Big pharma is using China-originated discovery as a portfolio fix, while Hengrui gets a global route for early science.
☕ Coffee talk At what point does China BD stop being opportunistic and become the pipeline plan?
3️⃣ FDA wants labels for drugs nobody is paid to chase FDA opened docket FDA-2026-N-4492 on repurposing approved drugs for unmet needs, targeting cases where evidence may exist but commercial incentives do not.
💡 Why it matters If FDA turns old evidence into label changes, it creates a different route for rare, chronic and neglected indications. The value may sit outside normal IP math.
☕ Coffee talk Who funds the study when the molecule is old and the label is the asset?